Form 4: Ligand Pharmaceuticals CFO Sells Shares to Cover Tax Obligations

Ligand Pharmaceuticals' Chief Financial Officer, Octavio Espinoza, sold 1,859 shares of common stock to cover tax liabilities related to the settlement of restricted stock units.

Summary

• Octavio Espinoza, the Chief Financial Officer of Ligand Pharmaceuticals, sold 1,859 shares of the company's common stock on December 5, 2024.
• The sale was executed at a price of $123.51 per share.
• This transaction was conducted to cover the tax obligations arising from the settlement of restricted stock units.
• Following the transaction, Mr. Espinoza directly owns 22,751 shares of Ligand Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the pharmaceutical industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar transactions by executives at other firms.
• The number of shares sold and the price are specific to this transaction and do not provide a direct comparison to other companies without further context.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
• The sale does not indicate any change in the company's fundamentals or future prospects.

Key Dates

Keywords

Ligand Pharmaceuticals, Octavio Espinoza, Chief Financial Officer, stock sale, restricted stock units, tax liability, insider trading